RadNet Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de RadNet han disminuido a una tasa media anual de -56.9%, mientras que en la industria Healthcare los beneficios crecieron en un 4.4% anualmente. Los ingresos han ido creciendo a una tasa media de 11.3% al año.
Información clave
-56.94%
Tasa de crecimiento de los beneficios
-57.77%
Tasa de crecimiento del BPA
| Crecimiento de la industria Healthcare | 8.50% |
| Tasa de crecimiento de los ingresos | 11.32% |
| Rentabilidad financiera | 1.63% |
| Margen neto | -0.66% |
| Próxima actualización de resultados | 10 Aug 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • Jun 24
RDNT: Advanced Imaging And AI Platform Expansion Will Support Future Earnings
RadNet's analyst price target has shifted lower by $5 to $65, with analysts pointing to both the recent target cuts from Barclays and B. Riley and ongoing confidence reflected in its inclusion on Jefferies' Franchise Picks list as key context for the revision.Actualización de narrativa • Jun 06
RDNT: Advanced Imaging And AI Execution Will Support Future Earnings
Narrative Update: RadNet The updated analyst price target for RadNet has shifted modestly lower to around $90 per share. This reflects analysts’ recalibration of fair value and discount rate assumptions, while also acknowledging continuing support from recent research that highlights the stock’s inclusion in high-conviction lists and its relative strength in advanced volume growth and imaging pricing versus peers.Artículo de análisis • May 14
Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report
Last week, you might have seen that RadNet, Inc. ( NASDAQ:RDNT ) released its quarterly result to the market. The early...Actualización de narrativa • May 07
RDNT: Imaging Platform Execution And New Idaho Venture Will Support Future Earnings
Analysts have trimmed their fair value estimate for RadNet by $0.50 to $89.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E after recent Street research, including a lower $4 price target from B. Riley and an upgrade of Lumexa Imaging at Raymond James.Actualización de narrativa • Apr 23
RDNT: Sector Sentiment Tailwinds Will Support Future Earnings Visibility
Analysts have trimmed their price target on RadNet by $2 to reflect slightly updated assumptions on fair value, future P/E and operating metrics, while incorporating recent Street research that highlights improved sentiment following the Raymond James upgrade of Lumexa Imaging. Analyst Commentary Bullish Takeaways Bullish analysts view the recent upgrade of Lumexa Imaging as a supportive read-through for sentiment around diagnostic imaging.Actualización de narrativa • Apr 08
RDNT: Outpatient Imaging Shift Will Support Future Earnings Visibility
RadNet's analyst price target now stands at $92. Analysts cite outpatient diagnostic imaging growth drivers, Medicare reimbursement support, potential capital deployment, and an AI ramp as key reasons for maintaining this level.Actualización de narrativa • Mar 25
RDNT: Outpatient Imaging Shift And AI Adoption Will Drive Future Upside
Analysts kept their $92 price target for RadNet unchanged, citing what they see as attractive long term growth drivers in outpatient diagnostic imaging, reasonable 2025 to 2028 company targets, supportive Medicare reimbursement trends, potential capital deployment benefits, and expected AI contributions. Analyst Commentary Bullish Takeaways Bullish analysts view outpatient diagnostic imaging as an attractive subsector, with hospital to outpatient shifts and growing demand for advanced imaging seen as key growth drivers that support RadNet's long term story and current valuation framework.Actualización de narrativa • Mar 09
RDNT: Outpatient Imaging Shift And AI Ramp Will Support Future Upside
Analysts have raised their price target on RadNet from $91.75 to $92.38. The updated target reflects revised assumptions that incorporate higher projected revenue growth, a lower profit margin outlook, and a higher future P/E multiple supported by recent bullish Street research on outpatient imaging and AI benefits.Actualización de narrativa • Feb 22
RDNT: Outpatient Imaging Shift And AI Adoption Will Support Future Upside
Analysts have trimmed their implied future P/E assumption for RadNet, leading to a slightly lower blended price target of about $97 vs. roughly $102 previously.Actualización de narrativa • Feb 08
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Support Upside
Analysts have raised their price target on RadNet to about $92, reflecting confidence in the outpatient diagnostic imaging segment and the company's 2025 to 2028 targets, including expected benefits from improved Medicare rates, potential capital deployment, and increasing AI contributions. Analyst Commentary Recent research reflects a generally constructive tone on RadNet, with several firms lifting price targets into the high US$80s to low US$90s range and highlighting both the core imaging business and longer term AI potential.Actualización de narrativa • Jan 24
RDNT: Outpatient Imaging Shift And AI Breast Screening Will Drive Upside
Analysts lifted their price target on RadNet to about US$91.75 from roughly US$91.71, reflecting recent coverage that highlights outpatient imaging growth drivers, supportive Medicare reimbursement, capital deployment options, and potential contributions from artificial intelligence (AI). Analyst Commentary Recent Street research on RadNet focuses on outpatient imaging growth, long term targets and the role of AI and capital allocation in supporting the current valuation framework.Actualización de narrativa • Jan 09
RDNT: Outpatient Imaging And AI Adoption Will Drive Future Outperformance
Analysts have raised their price target on RadNet to about US$92, citing what they view as reasonable 2025 to 2028 goals, supportive Medicare reimbursement trends, potential capital deployment upside, and growing contributions from AI and outpatient imaging demand. Analyst Commentary Recent research has focused on how RadNet's outpatient imaging footprint, AI initiatives, and long term financial targets could support its valuation and growth ambitions.Actualización de narrativa • Dec 13
RDNT: Integrated Offerings And Margin Expansion Will Drive Future Outperformance
Analysts have modestly increased their price target on RadNet, citing stronger long term growth and margin expansion prospects highlighted at the recent investor day and reflected in updated fair value estimates rising from about $91.71 to roughly $92.50 per share, alongside reaffirmed expectations for double digit revenue growth and mid teens EBITDA expansion. Analyst Commentary Bullish analysts highlight that the updated 2028 targets for double digit revenue growth and margin expansion underpin a durable mid teens EBITDA growth profile, which they view as supportive of further multiple expansion from current levels.Actualización de narrativa • Nov 28
RDNT: Sustained Demand And Integrated Offerings Will Drive Future Outperformance
Analysts have raised their price target for RadNet from approximately $87 to $93, citing higher revenue growth expectations and confidence in the company’s integrated offerings and sustained demand. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for RadNet, citing encouraging revenue growth expectations and confidence in the company’s ability to deliver sustained margin expansion.Artículo de análisis • Nov 14
Earnings Miss: RadNet, Inc. Missed EPS By 65% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that RadNet, Inc. ( NASDAQ:RDNT ) filed its third-quarter result this time last week...Actualización de narrativa • Nov 13
RDNT: Momentum Will Accelerate From Surging Demand And Integrated Offerings
RadNet’s analyst price target has increased from $80.57 to $86.67. This reflects confidence from analysts who cite strong demand, integrated offerings, and positive industry momentum as key drivers.Actualización de narrativa • Oct 30
RDNT: Imaging Center Demand And Digital Health Will Drive Measured Upside Potential
Analysts have increased their price target for RadNet from $74 to $81. They cite strong core imaging center demand and ongoing investments in digital health as key factors for the optimistic outlook.Actualización de narrativa • Oct 15
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet's analyst price target has been raised from $79.29 to $80.57 per share. This change reflects analysts' optimism amid strong imaging center demand, ongoing digital health investments, and potential M&A opportunities.Actualización de narrativa • Sep 19
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
RadNet’s consensus price target has risen to $79.29 as analysts cite robust imaging center demand, expanding service opportunities, strong digital health investments, and confidence in management’s strategic execution. Analyst Commentary Robust core imaging center demand trends indicate sustained growth potential.Artículo de análisis • Sep 12
RadNet (NASDAQ:RDNT) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Actualización de narrativa • Sep 04
AI Powered Imaging And Demographic Trends Will Accelerate Advanced Diagnostics
Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43. Analyst Commentary Robust core imaging center demand trends highlighted in recent management meetings.Seeking Alpha • Aug 18
RadNet: Bloated Capital Base Not Pulling Its Economic Weight (Rating Downgrade)
Summary I am downgrading RDNT stock to hold due to excessive capital requirements, bloated acquisitions, and declining returns on invested capital despite strong top-line growth. The valuation is stretched, with RadNet trading at 78x EBIT and >5x book value, while debt levels and working capital intensity have surged. Operating margins are compressing, free cash flow yields have turned negative, and acquisitions are not delivering sufficient economic returns. I will reconsider a more bullish stance only if RDNT demonstrates margin expansion, improved capital productivity, or stronger free cash flow generation. Read the full article on Seeking AlphaArtículo de análisis • Jul 31
Some Confidence Is Lacking In RadNet, Inc.'s (NASDAQ:RDNT) P/S
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Seeking Alpha • Mar 11
RadNet: On The Sidelines For Now
Summary RDNT's stock performance has been lackluster, with only an 8.8% increase over the past year, currently trading at $50 per share. Despite decent fundamentals, including steady revenue growth and strong operating cash flow, RDNT faces risks from wage increases and weather-related disruptions. Recent market overreaction to temporary weather impacts presents a potential rebound opportunity, but the projected 8.6% return does not justify the investment risk. I rate RDNT as neutral due to uncertainties in revenue growth and bottom-line pressures, suggesting better opportunities elsewhere with more favorable risk-reward profiles. Read the full article on Seeking AlphaSeeking Alpha • Oct 02
RadNet: Secular Tailwinds Underpinned By AI Monetization Prospects
Summary RadNet, the largest US diagnostic imaging operator, projects $1.8bn in 2024 revenue, driven by AI and Digital Health growth, and expanding imaging centers. Strong Q2 results with 13.9% revenue growth and 19.7% EBITDA increase, fueled by AI advancements and new imaging center openings. Future growth catalysts include market shifts to freestanding centers, increasing importance of joint ventures, and capital deployment for acquisitions and new facilities. Digital Health and AI initiatives, like DeepHealth OS and EBCD, are expected to drive significant revenue and margin expansion. Read the full article on Seeking Alpha
Nueva narrativa • Aug 30
Expanding Imaging Modalities And AI Integration Signal Strong Future Growth In Healthcare Sector
Expansion into advanced imaging and integration of AI technologies aim at boosting revenue through higher reimbursement rates and operational efficiencies.Seeking Alpha • Aug 24
RadNet: Growth In Operating Earnings Off Very Little Incremental Capital
Summary RDNT stock is up 10% since my June publication following a strong set of quarterly numbers in its Q2 FY'24 earnings. Management continue executing on the growth route, recycling funds into new store openings. Same-store procedure volumes continue to ratchet higher, evidencing increased utilization of its legacy base. Net-net, reiterate buy. Read the full article on Seeking AlphaSeeking Alpha • Jun 05
RadNet: Qualified Growth Route, Still Undervalued
Summary RadNet, Inc. shares continue to show strength, having compounded by 184% since 2022. Q1 FY 2024 earnings showed growth in the Digital Health segment and increased MRI, CT, and PET/CT volumes. Management has increased its outlook on full-year revenues and projects $1.67-$1.7 billion in revenue for the year. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
RadNet, Inc. Stock Price Is More Vigorous Than Its Valuation
Summary RadNet, Inc. is assessed as a Buy opportunity especially on price dips for retail value investors; watch its valuation and growth ratings. The company's share price has seen significant growth recently but may drop due to volatility and potential missed estimates. RadNet is at the forefront of the movement to bring diagnostic imaging services out of hospitals, offering lower costs and increased accessibility. Read the full article on Seeking AlphaDesglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero RadNet. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 2,144 | -14 | 116 | 0 |
| 31 Dec 25 | 2,040 | -19 | 116 | 0 |
| 30 Sep 25 | 1,970 | -13 | 110 | 0 |
| 30 Jun 25 | 1,908 | -15 | 110 | 0 |
| 31 Mar 25 | 1,869 | -32 | 110 | 0 |
| 31 Dec 24 | 1,830 | 3 | 110 | 0 |
| 30 Sep 24 | 1,773 | -4 | 16 | 0 |
| 30 Jun 24 | 1,714 | 10 | 45 | 0 |
| 31 Mar 24 | 1,658 | 21 | 75 | 0 |
| 31 Dec 23 | 1,617 | 3 | 104 | 0 |
| 30 Sep 23 | 1,580 | 4 | 140 | 0 |
| 30 Jun 23 | 1,528 | -13 | 142 | 0 |
| 31 Mar 23 | 1,479 | -13 | 143 | 0 |
| 31 Dec 22 | 1,430 | 11 | 107 | 0 |
| 30 Sep 22 | 1,382 | 8 | 1 | 0 |
| 30 Jun 22 | 1,365 | 23 | 1 | 0 |
| 31 Mar 22 | 1,344 | 18 | 1 | 0 |
| 31 Dec 21 | 1,324 | 25 | 0 | 0 |
| 30 Sep 21 | 1,297 | 35 | 199 | 0 |
| 30 Jun 21 | 1,256 | 24 | 115 | 0 |
| 31 Mar 21 | 1,138 | 11 | 110 | 0 |
| 31 Dec 20 | 1,098 | -15 | 0 | 0 |
| 30 Sep 20 | 1,090 | -10 | 106 | 0 |
| 30 Jun 20 | 1,091 | -13 | 108 | 0 |
| 31 Mar 20 | 1,164 | 2 | 133 | 0 |
| 31 Dec 19 | 1,154 | 15 | 0 | 0 |
| 30 Sep 19 | 1,111 | 33 | 24 | 0 |
| 30 Jun 19 | 1,060 | 35 | 99 | 0 |
| 31 Mar 19 | 1,015 | 36 | 90 | 0 |
| 31 Dec 18 | 975 | 32 | 0 | 0 |
| 30 Sep 18 | 953 | -4 | 85 | 0 |
| 30 Jun 18 | 939 | -6 | 83 | 0 |
| 31 Mar 18 | 925 | -6 | 59 | 0 |
| 31 Dec 17 | 922 | 0 | 0 | 0 |
| 30 Sep 17 | 912 | 11 | 77 | 0 |
| 30 Jun 17 | 909 | 9 | 74 | 0 |
| 31 Mar 17 | 897 | 7 | 75 | 0 |
| 31 Dec 16 | 885 | 7 | 74 | 0 |
| 30 Sep 16 | 875 | 5 | 75 | 0 |
| 30 Jun 16 | 859 | 11 | 76 | 0 |
| 31 Mar 16 | 845 | 11 | 74 | 0 |
| 31 Dec 15 | 810 | 8 | 72 | 0 |
| 30 Sep 15 | 779 | 11 | 70 | 0 |
Ingresos de calidad: RDNT actualmente no es rentable.
Margen de beneficios creciente: RDNT actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: RDNT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 56.9% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de RDNT en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: RDNT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare (16%).
Rentabilidad financiera
Alta ROE: RDNT tiene una rentabilidad financiera negativa (1.63%), ya que actualmente no es rentable.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/27 09:41 |
| Precio de las acciones al final del día | 2026/07/27 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
RadNet, Inc. está cubierta por 12 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Sarah James | Barclays |
| Andrew Mok | Barclays |
| Yuan Zhi | B. Riley Securities, Inc. |